Bill Commons

MO SB 1621

died on adjournment

Establishes provisions relating to civil actions involving medical monitoring

Missouri · 2026 Regular Session · upper

Follow this bill’s action updates (Atom)

Subscribe in a feed reader. The feed covers recorded actions from the last 30 days; Bill Commons may record an action after it happened at the legislature.

Quick answers

Did MO SB 1621 pass?

No. MO SB 1621 died when the 2026 Regular Session adjourned without final action on it. Bills that die this way are sometimes reintroduced in a later session. Latest recorded action (2026-02-04): S First Read

What is MO SB 1621 about?

SB 1621 - This act provides that there shall be no standalone cause of action for medical monitoring in this state. Additionally, regardless of the legal theory asserted, an increased risk of disease shall not compensable by itself through damages or any other form of relief. No defendant shall be required to pay damages or provide other relief for a plaintiff's future medical monitoring unless the plaintiff proves, in addition to the requirements for the underlying cause of action, the following: • The future monitoring is directly related to, and necessitated by, a presently existing and diagnosable physical disease or injury of the plaintiff; • The future monitoring is distinct from other monitoring recommended in the absence of the preexisting physical disease or injury and related exposure; and • The plaintiff's presently existing physical disease or injury was caused by the defendant's tortious conduct. Furthermore, the mere presence of a toxic substance in the bloodstream shall not constitute a presently existing and diagnosable physical disease or injury. This act is identical to HB 2888 (2026). KATIE O'BRIEN

Who sponsors MO SB 1621?

Gregory (21), Kurtis is the primary sponsor of MO SB 1621.

Description

SB 1621 - This act provides that there shall be no standalone cause of action for medical monitoring in this state. Additionally, regardless of the legal theory asserted, an increased risk of disease shall not compensable by itself through damages or any other form of relief. No defendant shall be required to pay damages or provide other relief for a plaintiff's future medical monitoring unless the plaintiff proves, in addition to the requirements for the underlying cause of action, the following: • The future monitoring is directly related to, and necessitated by, a presently existing and diagnosable physical disease or injury of the plaintiff; • The future monitoring is distinct from other monitoring recommended in the absence of the preexisting physical disease or injury and related exposure; and • The plaintiff's presently existing physical disease or injury was caused by the defendant's tortious conduct. Furthermore, the mere presence of a toxic substance in the bloodstream shall not constitute a presently existing and diagnosable physical disease or injury. This act is identical to HB 2888 (2026). KATIE O'BRIEN

Introduced
—
Latest action
2026-02-04 — S First Read
Bill type
bill
Last updated
—

Sponsors

  • Gregory (21), Kurtisprimary

Committees

Not provided by source.

Action timeline

Newest first

  1. 2026-02-12

    Second Read and Referred S General Laws Committee

    reading-2,referral-committee

  2. 2026-02-04

    S First Read

    reading-1

Versions

Documents

Votes

Not provided by source.

Related bills

No related bills recorded for this bill.

Official source

Attribution

Data from openstates_api_sync, retrieved 2026-08-21T21:08:48.597527Z

Inspect retained evidence for changes recorded after evidence tracking began:

Session-wide evidence can include changes to other bills:

Use this data

Every field on this page is available from the free public API — no key or licence required. Fetch this bill as JSON: GET /api/v1/bills?jurisdiction=MO&identifier=SB 1621. See the API docs or the MCP server for AI assistants.

Known limitations

  • Sponsor party and chamber affiliation are not yet captured by this API.
  • Committee referrals are not yet captured.

See the methodology page for data sources and limitations.